Effective IMPD Writing. The Quality Part

Webinar: Effective IMPD Writing. The Quality Part

Effective IMPD writing, including the quality part is a vital document that contains information about an investigational medicinal product and it is an essential part of the Clinical Trial Application (CTA), which is required by competent authorities in EU.

The purpose of this webinar is to share the best practices in the preparation of IMPD in order to meet the expectations of competent authorities and to learn why effective CMC technical writing is crucial for the development of a high quality IMPD.

 

You will learn about:

1. Regulatory guidelines for the Investigational Medicinal Product Dossier

2. IMPD structure and content

3. Best practices for the preparation of IMPD

  • Best practices in IMPD Quality writing;
  • Writing style to produce accurate, concise, and clear technical text.

 

Starting Clinical Trials?

Make use of our expertise to smoothly prepare for clinical studies. Explore your options in a chat with one of our experts.

Who should attend? Professionals from the following fields:

  • Regulatory
  • R&D
  • QA/QC
  • Compliance
  • Product Development
  • Manufacturing

Duration: 40 min.

Speakers:

  • Head of the Central Functions for Regulatory Affairs, Ramunė Rūkienė;
  • Medical Writer, Eglė Deimantavičiūtė.
Ramunė Rūkienė, MSc

Ramunė Rūkienė, MSc

Head of Regulatory Affairs Central Operations

Other content that might interest you:

Medical Device Registration in Russia. Challenges and Issues

Medical Device Registration in Russia. Challenges and Issues

Webinar: Medical Device Registration in Russia. Challenges and Issues The purpose of this webinar is to show the differences and specifics of regulations and law processes that can cause challenges in medical device registration in Russia.   You will learn about:...

read more
eCTD Submission Strategies: In-house vs. Outsourcing

eCTD Submission Strategies: In-house vs. Outsourcing

Webinar: eCTD Submission Different Strategies: In-house vs. Outsourcing eCTD Submission Strategies, including outsourcing, are influenced by varying requirements in various regions and countries. That and diverse technical resources by companies often lead to various...

read more
Challenges In Early Phase Oncology Trials

Challenges In Early Phase Oncology Trials

Cancer is the biggest cause of mortality globally, with 19.3 million new cases and over 10 million deaths expected in 2020. By 2040, the worldwide cancer burden is predicted to reach 28.4 million cases. Female breast cancer is the most often diagnosed type of cancer,...

read more

Big Enough To Cover  All Your Needs. Small Enough To Care.

Discover the tailored solutions that Biomapas provides to accelerate your clinical trials and optimize your drug development process.

Clinical Research

Regulatory Affairs

Pharmacovigilance

Medical Information